These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33207828)

  • 1. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
    Brownstein MJ; Simon NG; Long JD; Yankey J; Maibach HT; Cudkowicz M; Coffey C; Conwit RA; Lungu C; Anderson KE; Hersch SM; Ecklund DJ; Damiano EM; Itzkowitz DE; Lu S; Chase MK; Shefner JM; McGarry A; Thornell B; Gladden C; Costigan M; O'Suilleabhain P; Marshall FJ; Chesire AM; Deritis P; Adams JL; Hedera P; Lowen K; Rosas HD; Hiller AL; Quinn J; Keith K; Duker AP; Gruenwald C; Molloy A; Jacob C; Factor S; Sperin E; Bega D; Brown ZR; Seeberger LC; Sung VW; Benge M; Kostyk SK; Daley AM; Perlman S; Suski V; Conlon P; Barrett MJ; Lowenhaupt S; Quigg M; Perlmutter JS; Wright BA; Most E; Schwartz GJ; Lamb J; Chuang RS; Singer C; Marder K; Moran JA; Singleton JR; Zorn M; Wall PV; Dubinsky RM; Gray C; Drazinic C
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease.
    Maibach HT; Brownstein MJ; Hersch SM; Anderson KE; Itzkowitz DE; Damiano EM; Simon NG
    J Pers Med; 2022 Sep; 12(10):. PubMed ID: 36294700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study.
    Lee RJ; Coccaro EF; Cremers H; McCarron R; Lu SF; Brownstein MJ; Simon NG
    Front Syst Neurosci; 2013; 7():100. PubMed ID: 24376401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of the irritability scale in Huntington's disease patients with evidence of irritability or aggression.
    En-Hua Wang J; Simon NG; Brownstein MJ; Maibach HT; Maibach J; Anderson KE
    Parkinsonism Relat Disord; 2024 Jun; 123():106087. PubMed ID: 38640832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.
    Fabio KM; Guillon CD; Lu SF; Heindel ND; Brownstein MJ; Lacey CJ; Garippa C; Simon NG
    J Pharm Sci; 2013 Jun; 102(6):2033-2043. PubMed ID: 23471831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.
    Difede J; McAleavey AA; Emrich M; Jick A; Ovalles A; Wyka K; Spielman L; Olden M; Peskin M; Becket-Davenport C; Rubenstein A; Brownstein MJ; Damiano E; Itzkowitz D; Lu SF; Needell NJ; Kocsis JH; Gordon-Elliott JS; Simon NG
    Contemp Clin Trials Commun; 2023 Jun; 33():101116. PubMed ID: 37008794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
    Lago TR; Brownstein MJ; Page E; Beydler E; Manbeck A; Beale A; Roberts C; Balderston N; Damiano E; Pineles SL; Simon N; Ernst M; Grillon C
    Psychopharmacology (Berl); 2021 Sep; 238(9):2393-2403. PubMed ID: 33970290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
    McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group.
    Neurology; 1998 May; 50(5):1366-73. PubMed ID: 9595988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).
    van Duijn E; Craufurd D; Hubers AA; Giltay EJ; Bonelli R; Rickards H; Anderson KE; van Walsem MR; van der Mast RC; Orth M; Landwehrmeyer GB;
    J Neurol Neurosurg Psychiatry; 2014 Dec; 85(12):1411-8. PubMed ID: 24828898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
    Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
    Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Course of irritability, depression and apathy in Huntington's disease in relation to motor symptoms during a two-year follow-up period.
    van Duijn E; Reedeker N; Giltay EJ; Eindhoven D; Roos RA; van der Mast RC
    Neurodegener Dis; 2014; 13(1):9-16. PubMed ID: 23948661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
    Kieburtz K; McDermott MP; Voss TS; Corey-Bloom J; Deuel LM; Dorsey ER; Factor S; Geschwind MD; Hodgeman K; Kayson E; Noonberg S; Pourfar M; Rabinowitz K; Ravina B; Sanchez-Ramos J; Seely L; Walker F; Feigin A;
    Arch Neurol; 2010 Feb; 67(2):154-60. PubMed ID: 20142523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.